T3 Pharmaceuticals

Executive Summary

T3 Pharmaceuticals is a Swiss biotechnology company pioneering a next-generation bacterial cancer therapy platform. Founded in 2015 and headquartered in Basel, the company engineers live bacteria to deliver therapeutic payloads directly into the tumor microenvironment, offering a highly targeted approach to oncology. By exploiting the natural tumor-homing properties of bacteria, T3 aims to overcome limitations of conventional therapies, such as poor tumor penetration and systemic toxicity. The platform enables localized production of anti-cancer agents, potentially improving efficacy while reducing side effects. T3's focus on unmet needs in solid tumors positions it within the emerging field of bacterial-based immuno-oncology, which has attracted significant interest from both academia and pharmaceutical partners.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase I clinical trial for lead candidate35% success
• Q3 2026Publication of preclinical proof-of-concept data in peer-reviewed journal80% success
• Q4 2026Securing series B or strategic partnership financing40% success